Klas Therapeutics Limited

Melanoma skin cancer (MSC), is the 5th most common cancer in both men and women and kills more than 6 people each day in the UK alone. In the last decade, immunotherapies have shown great promise in treating this disease, but just over 50% of patients respond to this treatment. With a price-tag running at 100's of thousands of pounds for treatment per pat...

Advanced malignant melanoma (MM) was a cancer considered untreatable just over a decade ago, with an average life expectancy for patients of 6 - 10 months. Today, 50% of patients can expect to live for at least 5 years. This is because of the advent and availability of new treatment options, namely immunotherapy and targeted therapies. Whilst the introduc...

Klas Therapeutics Ltd. is a Northern Ireland based company founded in Feb. 2021\. The company has developed technology that is new and innovative for the treatment of non-resectable malignant melanoma (MM), the most aggressive form of skin cancer. The technology originates from research carried out at the School of Pharmacy and Pharmaceutical Sciences at ...

Melanoma, or skin cancer, is the 5th most common cancer in both men and women and kills more than 6 people each day in the UK alone. In the last decade, immunotherapies have shown great promise in treating this disease, but with just over 50% of patients respond to this treatment. With a price-tag running at 100's of thousands of pounds for treatment per ...